Inspirational after lunch speaker just announced:
Gerald Ratner, Former Chief Executive, Ratners jewellery, made famous for successfully rebuilding his jewellery brand after his own words almost destroyed it.
At this meeting you will:
- Save money, improve safety and increase efficacy in your Phase I clinical trials
- Understand the consequences of the TeGenero experience on phase I trials
- Avoid product failure by learning exactly how to satisfy your regulators
- Listen to case studies about creative, low cost design to speed Phase I studies
- Develop strategies for improving CRO selection and management
- Hear the latest industry and regulatory perspectives on how to successfully plan and run a QTc Study
- Establish safe and rational dose selection/escalation in FIM studies
- Learn from more than 40 Phase I experts!
Key speakers include:
- Professor Kent Woods, Chief Executive Officer, Medicines and Healthcare Products Regulatory Agency, MHRA
- Professor Sir Gordon Duff, Chairman, Commission on Human Medicines
- Dr John Warren, Medical Assessor, MHRA, Member Scientific Advice Working Party, EMEA
- Fethi Trabelsi, Director, Scientific and Regulatory Affairs Anapharm, a PharmaNet Development Group company
- Willem Jan Drijfhout, Senior Vice President Early Development Services, PRA International
- Dr Jal Chiesa MD FFPM ICR, Medical Director, Covance
- Harsukh Parmar, Director, Discovery Medicine, Respiratory & Inflammation Therapy Area, AstraZeneca
- Dr. Thomas Senderovitz, M.D., Vice President Global Exploratory Development, R&D, UCB
- Greet Musch, Head of Department, Research & Development, Federal Agency for Medicines and Health products, Belgium
- Inspirational after lunch speaker: Gerald Ratner, Former Chief Executive, Ratner’s Jewellery
- Colette Strnadova, Ph.D., Senior Scientific Advisor, Health Canada
- Gregory I. Berk, MD, Chief Medical Officer, SuperGen, Inc.
- Alun W. Bedding, Director, Biostatistics and Programming Development Partners, Drug Development Sciences, GlaxoSmithKline
- Dr. Priyadarshini Roy, Clinical Pharmacologist, Novartis, India
- Borje Darpo, Pharmaceutical Consultant, formerly Vice President, Chief Medical Officer, Daiichi Medical Research UK and USA
- Georg Ferber, Group Head, Biostatistics, Novartis Pharma AG
- Piet H. van der Graaf, Head of Pharmacokinetics & PK/PD, Department of PDM, Pfizer Global Research & Development, Sandwich UK
- Paola Tocchetti, Director Drug Metabolism and Pharmacokinetics, NicOx Research Institute
- Dr. Stefano Persiani, PhD, Director, Dept. of Drug Metabolism, Pharmacokinetics and Dynamics, Rottapharm spa
- Paul Cutler, Genomics Research, GlaxoSmithKline